Carasent (tidligere Apptix)

TekBot · april 16, 2024, 2:01pm

Carasent group signs contract to supply Medrave M4 to VGR

Västra Götalands Regionen and Medrave AB have today entered into an agreement
to implement Medrave to the EHR system Millennium. The annual recurring
revenue from the contract is NOK 11 million, where NOK 6 million is new
…

Vis børsmeldingen

revenue.

Västra Götalands Regionen (VGR) is changing EHR system and has in connection
with this change held a tender for a system for operational monitoring and
automatic reporting to quality registries. Medrave won the tender for a 6
years agreement to provide Medrave M4. This is partly replacing the agreement
Medrave has to supply Medrave M4 to the old EHR system.

The yearly value of the contract after the implementation process is NOK 11
million with an addition of NOK 2 million of consultancy revenue the first
year. VGR is also buying Medrave for the old EHR system and as long as they
continue to do so the NOK 4-5 million VGR is paying for that solution will be
subtracted. The new income will start once the implementation is complete
which is expected in November 2024.

Carasent CEO Daniel Öhman comments:

We are very glad that VGR wants to continue and increase the collaboration
with Medrave. It is an unrivaled system when it comes to follow-up of
primary care quality and automatic reporting to quality registries.

In a short period of time we have now signed the two largest customer
contracts in Carasent’s history. Signed but not implemented ARR is now
approximately NOK 14 million (NOK 6 million from the new VGR agreement) up
from NOK 2 million Q1 2023. Revenue growth is the key to drive our profit
margins given that we aim to keep the cost base flat, and this new ARR will
contribute significantly, as our gross margins are over 80%.

About Medrave Software AB

Founded in 1996, Medrave Software AB is a distinguished leader in healthcare
business intelligence solutions. Acquired by the Carasent Group in December
2021, Medrave offers an unparalleled BI platform, meticulously designed in
close collaboration with medical professionals. As Sweden’s premier solution
for accessing and visualizing patient record data, Medrave significantly
enhances operational workflows and the quality of care. It is currently used
by more than 90% of the primary healthcare centres and 1,000 outpatient
clinics across Sweden.

For further details please contact:

Daniel Öhman, CEO Tel: +46 70-855 37 07, or
Svein Martin Bjørnstad, CFO Tel: +47 979 69 493

Kilde

TekBot · april 17, 2024, 8:06am

Carasent ASA - Minutes from the Annual General Meeting

TekBot · april 19, 2024, 11:36am

Carasent ASA - Invitation to presentation of Q1 2024 results

TekBot · april 23, 2024, 2:31pm

Carasent ASA - announcement of revised financial targets

Carasent ASA (“Carasent” or the “Company”) is currently executing on its plan
to create long-term shareholder value, as explained on the Capital Markets Day
7 November 2023. Due to order inflow being significantly above expectations;
…

Vis børsmeldingen

better than anticipated success on cost savings; and continued low churn,
Carasent has improved visibility on the expected growth and profitability
during the coming years. The Company therefore revises the financial targets
as follows.

Financial targets 2024:

Revenues of NOK 270 million (15% organic growth)

EBITDA in excess of NOK 40 million

EBITDA – capex around NOK 0

EBITDA – capex of NOK 20 million excluding Webdoc X

Financial targets 2025:

Revenues above NOK 320 million (20% organic growth)

EBITDA of NOK 80 million

EBITDA – capex of NOK 40 million

EBITDA – capex of NOK 60 million excluding Webdoc X

Carasent is executing its strategy to reach targets with the current company
structure. Potential acquisitions and divestments are not included. The
financial targets are intended for a long-term perspective, and there will be
variations between quarters. The new targets replace the long-term financial
targets announced on 7 November 2023.

Carasent CEO Daniel Öhman comments:

| The strength of a business like ours, with minimal churn, strong growth and
| cost control, is that bottom line scales rapidly as revenues grow. The
| additional customer contracts and cost reductions lead us to believe that it
| is time to update our financial goals.

Note: EBITDA and EBITDA - capex is alternative performance measures as a
supplement to the financial statements prepared in accordance with IFRS.
Please see the latest quarterly report for further details.

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2024-04-23 16:31 CEST.

Kilde

TekBot · april 24, 2024, 5:00am

Carasent ASA - Q1 2024 financial results and presentation

TekBot · april 24, 2024, 5:08am

Carasent ASA - Q1 2024 presentation

TekBot · april 29, 2024, 6:06am

Contemplated voluntary cash offer to acquire all shares in Carasent ASA

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

EG Norge AS (“EG” or the “Offeror”) contemplates launching a voluntary cash offer to acquire all outstanding shares of Carasent ASA (“Carasent” or the "Company) at a price of NOK 20 per share (the “Offer”).
…

Vis børsmeldingen

The Offer represents a premium of (i) 81.8% to closing price the last trading day before Carasent published the Q1 2024 report including the revised financial targets (23 April 2024), (ii) 40.0% to the volume-weighted average price (“VWAP”) since publishing the Q1 2024 report (24 April 2024), and (iii) 78.0% to the last 30 trading days VWAP prior to Carasent publishing the Q1 2024 report.

The Offer has already received strong support from key shareholders representing 34.0 per cent of the share capital of the Company, who have given irrevocable undertakings to, subject to customary conditions, accept the Offer once launched. Acceptance undertakings representing 31.3% of the share capital of the Company may only be withdrawn if the offer period in respect of the Offer is not commenced on or prior to 16:30 (CEST time) on 31 July 2024 or a third party makes a competing offer with a consideration representing at least a 50% premium to the Offer Price that is not matched by the Offeror.

It is expected that the Offer will be subject to customary conditions, including acceptance level and any regulatory approvals required. The Offer will not be subject to or conditional upon financing.
EG is a market leading vendor of Nordic vertical software for private and public customers. EG’s Software-as-a-Service offerings are developed by specialists with deep industry and domain knowledge, supporting business-critical and administrative processes.

" We are impressed with the scale and quality of the business that the Carasent team has built. In our view, there is a clear strategic fit between Carasent and EG. Combining the forces of Carasent and EG will enable us to create an even stronger player within healthcare and social care. It requires scale to fully capture the opportunities and win in the rapidly changing market.

We therefore believe a combination of Carasent and EG will be in the best interest of the employees, customers and other stakeholders of the two companies " says Mikkel Bardram, CEO of EG.

Launch of the Offer is subject to, inter alia, a customary confirmatory due diligence of key commercial, financial, technical and legal aspects of the Company with a focus on confirming key assumptions. EG will do so with an experienced team who have conducted more than 35 acquisitions in the past four years, and looks forward to engaging with the Carasent management team to complete the confirmatory due diligence without delay.

EG initiated formal contact with the board of directors of Carasent on 4 April 2024 by submitting an indicative offer letter outlining key terms of the Offer. EG had at that time already received strong support from shareholders representing 31.3% per cent of the share capital of the Company, including the Company’s largest shareholder, Acapital Cara Holdco AS and a group consisting of Johan Lindqvist, former Chairman, Dennis Höjer, former CEO, Niclas Hugosson, founder and CPO in Carasent, and Jesper Jannerberg, former CEO.

Based on the strong offer and key shareholder support, EG requested customary due diligence access in order to be able to confirm key offer assumptions. However, EG and the board of directors of Carasent have to date not been able to reach an agreement for EG to commence its confirmatory due diligence. The board of directors has, inter alia, required that EG commits to not making the offer known to the shareholders in Carasent in the event the board ultimately decides not to recommend the Offer. EG cannot accept to limit its ability to let the shareholders themselves consider whether or not to accept the Offer. EG has therefore not seen any other option than to announce its intention to launch the Offer, while reiterating its request to the board of directors of Carasent to allow EG to conduct a confirmatory due diligence without undue delay. EG is of the firm opinion that a public announcement of its intention to launch the Offer is in the best interest of all stakeholders of Carasent, including its shareholders, employees and customers.

As further evidence of the attractiveness of the Offer, EG has over the past few days secured additional irrevocable undertakings to accept the Offer from shareholders representing 2.7 per cent, bringing the total up to 34.0 per cent of the share capital of the Company.

The complete details of any launched Offer, including all terms and conditions, will be included in an offer document (the “Offer Document”) to be sent to the Company’s shareholders. This notification does not constitute an offer. The Offer will only be made on the basis of the Offer Document and can only be accepted pursuant to the terms of the Offer Document. The Offer will not be made in any jurisdiction in which the making of the Offer would not be in compliance with the laws of such jurisdiction.

Carnegie AS is acting as financial advisor to EG in connection with the Offer, and Arntzen de Besche Advokatfirma AS is acting as legal advisor.

CONTACT

Per Roholt, Communications Manager, +45 2060 9736, peroh@eg.dk

The Offer and the distribution of this announcement and other information in connection with the Offer may be restricted by law in certain jurisdictions. The Offeror assumes no responsibility in the event there is a violation by any person of such restrictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.
This release contains certain forward-looking statements within the meaning of the securities laws and regulations of various international, federal, and state jurisdictions. All statements, other than statements of historical fact, included herein, including without limitation, statements regarding the Offer, future plans and objectives of the Offeror are forward-looking statements that involve risk and uncertainties. There can be no assurances that such statements will prove to be accurate and actual results could differ materially from those anticipated in such statements.

Kilde

TekBot · april 29, 2024, 7:57am

CARASENT COMMENTS ON EG S INTENTION TO LAUNCH VOLUNTARY CASH OFFER

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL.
…

Vis børsmeldingen

Carasent ASA (“Carasent”) refers to today’s stock exchange release from EG A/S
(“EG”) regarding EG’s intention to make a cash tender offer for all shares in
Carasent.

Carasent confirms that EG has made an approach to carry out due diligence with
a view to making an offer, subject to acceptance in respect of at least 80% of
all shares and other conditions. Carasent has let EG know that the board of
directors will not be able to recommend an offer at NOK 20 per share. This
price clearly does not attribute enough value to Carasent’s value creation
plan and potential synergies. Taking into account that there could be an
industrial rationale for a transaction in combining Carasent and EG as
competitors in certain markets, Carasent has expressed that it is willing to
permit EG to carry out due diligence to underpin a higher valuation and price
that could form the basis for a recommended offer. It has requested EG to
agree to a short standstill period to allow EG the benefit of the
pre-acceptances it had obtained before approaching Carasent, while conducting
due diligence and allowing for negotiation of an offer that can be
recommended. This would not have restricted EG from making an offer, even one
that is not recommended, after such stand-still period.

Vitruvian Partners, who, through a subsidiary, owns 16.6% of the shares in
Carasent, and who is represented on the board of directors by Tomas Meerits,
have let the board of directors know it is not minded to accept an offer at
the NOK 20 level, which means it would have been unlikely to reach the 80%
acceptance level originally indicated by EG as a requirement to complete a
transaction.

Carasent has also received expressions of interest from several other parties
in a potential take-over by way of a voluntary offer to shareholders, none of
which contain a proposed price. Like EG’s, none of these expressions of
interest have been of a binding nature.

Carasent is currently executing on its plan to create long-term shareholder
value. Due to order inflow being significantly above expectations; better than
anticipated success on cost savings; and continued low churn, Carasent has
improved visibility on the expected growth and profitability during the coming
years. Reference is made to Carasent’s release 23 April 2024.

As communicated on the Capital Markets Day 7 November 2023, Carasent has
continued work on a potential relisting of Carasent’s shares from the Oslo
Stock Exchange to Nasdaq Stockholm. It is currently anticipated that this move
will be carried out in the end of 2024 by Carasent ASA merging with a
wholly-owned Swedish subsidiary (“Carasent AB (publ)”), which will survive the
merger, to the effect that shareholders will have their Carasent shares listed
only on the Oslo Stock Exchange exchanged one for one with Carasent AB (publ)
shares) listed only on Nasdaq Stockholm.

On the basis of the plan and status of execution of the plan, the board of
directors has been reluctant to engage with any party showing an interest in
Carasent. With Carasent ahead of its value creation plan, the reservations
about engaging in exploring potential transactions that could capture value
for shareholders are at this point in time less weighty than they have been
until now. The board of directors will only recommend offers that attribute
adequate value to the plan and to any synergies. Carasent may now seek to
entertain discussions with and permit due diligence by one or several of the
parties who have expressed interest, including EG.

It is not known whether any such discussions will result in any proposed
transaction or the price and other terms of such proposed transaction, be it
in the form of a voluntary offer for Carasent’s shares or in any other form.

Carasent does not intend to make any public announcement in respect of any
such discussions unless and until such discussions might have resulted in any
definitive agreement in respect of any such proposed transaction.

If EG makes the offer it has announced this morning, the board of directors
will make its statement in respect of such offer as required by law.

The board of directors advises all shareholders to monitor the situation but
not take any action in respect of the offer which may be made by EG until
shareholders can assess the merits of such offer on the basis of further
developments.

The board of directors will, as always, work to maximize value for
shareholders.

Carasent has engaged DNB Markets and BAHR to advise it in respect of the
interest by EG and others.

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2024-04-29 09:56 CEST.

Kilde

TekBot · mai 3, 2024, 2:32pm

CARASENT COMMENTS FURTHER ON EG S INTENTION TO LAUNCH VOLUNTARY CASH OFFER

The offer is likely to be rejected by above 39% of shareholders unless price
is significantly increased.

…

Vis børsmeldingen

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL.

Carasent ASA (“Carasent”) refers to the stock exchange release from EG A/S
(“EG”) 29 April 2024 regarding EG’s intention to make a cash tender offer for
all shares in Carasent at NOK 20 per share and Carasent’s immediate comments
in a subsequent stock exchange release.

In response to Carasent’s communication that it may seek to entertain
discussions and permit due diligence with interested parties, shareholders
holding above 39% of the shares have informed Carasent that they are not
minded to accept any offer which is not significantly above the level proposed
by EG. This includes the 16.6% stake of Vitruvian Partners.

Due to EG’s announced intention to make an offer, Carasent presently remains
inclined to continue to discuss opportunities for a transaction with EG and
others. It is not known whether any such discussions will result in any
proposed transaction or the price and other terms of such proposed
transaction, be it in the form of a voluntary offer for Carasent’s shares or
in any other form.

Carasent does not intend to make any public announcement in respect of any
such discussions unless and until such discussions might have resulted in any
definitive agreement in respect of any such proposed transaction.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 the Norwegian Securities Trading Act.

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2024-05-03 16:31 CEST.

Kilde

TekBot · juni 24, 2024, 5:00am

Carasent group signs contract to supply Ad Curis to Frelsesarmeen

Frelsesarmeen and Carasent Norway have entered into an agreement to implement
the EHR system Ad Curis at Frelsesarmeen’s addiction care and recovery clinics
in Norway. The annual recurring revenue from the contract is NOK 3.3 million.
…

Vis børsmeldingen

The contract also includes NOK 6 million of consulting revenue.

Frelsesarmeen has 20 clinics providing addiction care and recovery, which will
now replace their current EHR with Ad Curis.

The yearly value of the contract after the implementation process is NOK 3.3
million, with an addition of NOK 6 million of consultancy revenue during the
implementation period, estimated to be from June until the end of 2025.

Carasent CEO Daniel Öhman comments:

| We are very pleased that Frelsesarmeen has chosen Ad Curis as their core
| system to support their forward-thinking digitalisation strategy.

| Carasent continues to win new contracts, ensuring accelerated and profitable
| growth. Signed but not implemented ARR is now approximately NOK 17 million,
| up from NOK 2 million in Q2 2024. Revenue growth is key to driving our
| profit margins, given that we aim to keep the cost base flat. This new ARR
| will contribute significantly, as our gross margins are over 80%.

About Ad Curis

Ad Curis is a cloud-based EHR software especially designed to meet the unique
needs of professionals working in addiction care and recovery. Its innovative
solutions streamline workflows and enhance the quality of care, empowering
healthcare providers to work more efficiently and in closer collaboration with
patients.

For further details please contact:

Daniel Öhman, CEO Tel: +46 70-855 37 07, or
Svein Martin Bjørnstad, CFO Tel: +47 979 69 493

Kilde

TekBot · juli 4, 2024, 7:40pm

EG INFORMS CARASENT IT WILL NOT MAKE CONTEMPLATED TAKE-OVER OFFER

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL.
…

Vis børsmeldingen

Carasent ASA (“Carasent”) refers to the stock exchange release from EG A/S
(“EG”) on 29 April 2024 regarding EG’s contemplating to make a cash tender
offer for all shares in Carasent at NOK 20 per share and Carasent’s comments
in the subsequent stock exchange releases on the same day and on 3 May 2024.
As Carasent communicated in those releases, such an offer would in the view of
the board of directors of Carasent, (i) represent a significantly lower value
to the shareholders of Carasent inherent in Carasent’s business plan on a
stand-alone basis and (ii) be unlikely to succeed based on communications with
shareholders.

EG has on 4 July 2024 after close of trading on Oslo Børs informed Carasent
that it has decided not to proceed with the making of any offer.

Carasent will make no further comments in relation to the interest shown by
EG.

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2024-07-04 21:40 CEST.

Kilde

TekBot · juli 8, 2024, 8:17am

Carasent ASA - Invitation to presentation of Q2 2024 results

TekBot · juli 12, 2024, 5:01am

Carasent ASA - Q2 2024 report and presentation

TekBot · august 30, 2024, 6:00am

Carasent ASA - Announcement of cross border merger in connection with relisting to Stockholm

Carasent’s board of directors has resolved on a cross-border merger plan to
effect the planned relisting of its shares on Nasdaq Stockholm

…

Vis børsmeldingen

The board of directors of Carasent ASA (“Carasent” or the “Company”) has today
resolved to adopt a merger plan for a cross-border merger, subject to approval
by an extraordinary general meeting in Carasent, with a newly established
wholly-owned Swedish subsidiary[1] under name change to Carasent AB (publ)
(“Carasent SWE”). The cross-border merger is, as previously announced,
intended to be carried out by Carasent merging with Carasent SWE with the
latter as acquiring entity, to the effect that shareholders will have their
Carasent shares one for one exchanged with Carasent SWE shares listed only on
Nasdaq Stockholm (the “Relisting”).

The Company’s intention to relist has been previously announced at 2023’s
Capital Markets Day, as well as in recent quarterly reports. A majority of
Carasent’s operations and customer base are located in Sweden - approx. 80% of
revenue as of FY 23 was generated in the country. Furthermore, the Company
believes that such listing on Nasdaq Stockholm will enhance share liquidity
and attract a broader shareholder base. Against this background, the board of
directors of the Company has resolved to adopt a merger plan for a
cross-border merger, to facilitate the Relisting.

The Company intends to relist its shares on Nasdaq Stockholm by transferring
the business currently operated in Carasent to Carasent SWE, whose shares will
subsequently be listed on Nasdaq Stockholm. For this purpose, the board of
directors of Carasent has today adopted a merger plan pursuant to which the
assets and liabilities of Carasent will be transferred to Carasent SWE through
a cross-border merger by way of absorption. Carasent SWE is a Swedish
wholly-owned subsidiary of the Company and has no operations of its own.
Subsequent to completion of the cross-border merger, the shareholder
structure, board of directors and management of Carasent SWE will be identical
to the current shareholder structure, board of directors and management of
Carasent. Carasent SWE will be described in more detail in a listing
prospectus to be approved by the Swedish Financial Supervisory Authority,
which will contain practical information for shareholders with respect to
delivery and trading of their Carasent SWE shares after Relisting. Completion
of the cross-border merger is conditional upon, inter alia, obtaining relevant
approvals from Nasdaq Stockholm and relevant governmental authorities. The
cross-border merger and Relisting are estimated to be completed during
December 2024. Further information on key dates etc. will follow.

The cross-border merger requires a resolution by the extraordinary general
meeting (“EGM”) of the shareholders of Carasent. Further information and the
proposed resolutions will be included in the notice of the EGM which will be
announced separately within short. The EGM is planned to be held in early
October 2024.

The merger plan for the cross-border merger together with appended
documentation and other relevant documents are available at the Company’s
website and will free of charge be sent to those shareholders who so request
and state their postal address.

For further information, please contact

Daniel Öhman, CEO Tel: +46 70-855 37 07, or
Svein Martin Bjørnstad, CFO Tel: +47 979 69 493

[1] The current name of the company is Goldcup 101292 AB (publ) (u.n.c.t
Carasent AB (publ)).

Kilde

TekBot · september 10, 2024, 6:01am

Carasent ASA - Calling notice for extraordinary general meeting

TekBot · september 27, 2024, 2:36pm

Carasent ASA incentive program for chairman and CEO to be replaced by investments in Carasent SWE shares

Reference is made to Carasent ASA’s (“Carasent” or the “Company”) stock
exchange and press release 30 August 2024 regarding the merger plan for a
cross-border merger to the effect that shareholders will have their Carasent
…

Vis børsmeldingen

shares one for one exchanged with Carasent SWE shares listed only on Nasdaq
Stockholm (the “Relisting”). Further reference is made to the Company’s stock
exchange and press release 3 October 2022 regarding sale of warrants under
stock option program with terms of four (50% of the options) and five (50% of
the options) years to the chairman of the board of directors for NOK 800,000
and for the CEO for NOK 800,000.

Warrants in Carasent ASA cannot be continued in their current form after the
cross-border merger. The Company has agreed with each of the chairman and the
CEO that the warrants sold each of them by the Company in 2022 will be
cancelled, subject to, and, immediately prior to, the consummation of the
cross-border merger and Relisting. The Company will refund the purchase prices
they paid. The chairman and the CEO will use the amounts to be refunded in
open-market purchases of Carasent SWE shares. Carasent SWE will succeed to
Carasent’s rights to enforce the agreement pursuant to the merger plan for the
cross-border merger.

The cross-border merger remains subject to approval by the Company’s
shareholders at the extraordinary general meeting to be held on 4 October 2024
and to other conditions precedent, inter alia, obtaining relevant approvals
from Nasdaq Stockholm and relevant governmental authorities.

For further information, please contact
Svein Martin Bjørnstad, CFO Tel: +47 979 69 493

Kilde

TekBot · oktober 4, 2024, 7:31am

Carasent ASA Extraordinary general meeting has approved cross-border merger to effect relisting to Nasdaq Stockholm

Reference is made to Carasent AS s (“Carasent” or the “Company”) stock
exchange and press release 30 August 2024 regarding the merger plan for a
cross-border merger to the effect that shareholders will have their Carasent
…

Vis børsmeldingen

shares one for one exchanged with Carasent SWE shares listed only on Nasdaq
Stockholm (the “Relisting”) and to the calling notice 10 September 2024 for an
extraordinary general meeting to resolve on the proposed cross-border merger
to be held today.

The extraordinary general meeting has been held today. The cross-border merger
was approved.

Please find attached the minutes with attachments from today’s extraordinary
general meeting in Carasent ASA (“Carasent”).

The cross-border merger and Relisting are estimated to be completed during
December 2024.

Further information on key dates etc. will follow. The cross-border merger
remains subject to conditions precedent, inter alia, obtaining relevant
approvals from Nasdaq Stockholm and relevant governmental authorities.

For further information, please contact:

Petri Nemi, Chairman of the Board Tel: +358 40 051 149

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-10-04 09:30 CEST.

Kilde

TekBot · oktober 4, 2024, 7:33am

Carasent ASA Certain practical information to shareholders in connection with contemplated relisting to Nasdaq Stockholm

Reference is made to Carasent AS s (“Carasent” or the “Company”) stock
exchange and press release 30 August 2024 regarding the merger plan for a
cross-border merger to the effect that shareholders will have their Carasent
…

Vis børsmeldingen

shares one for one exchanged with Carasent SWE shares listed only on Nasdaq
Stockholm (the “Relisting”), and to the Company s stock exchange and press
release today that the cross-border merger has been approved by the Company s
extraordinary general meeting.

The Company hereby publishes the attached practical information to
shareholders in preparation of the contemplated Relisting.

This and other information about the cross-border merger is available on the
Company s website www.carasent.com.

For further details please contact:

Svein Martin Bjørnstad, CFO Tel: +47 979 69 493

Kilde

TekBot · oktober 21, 2024, 4:00pm

Carasent ASA - Invitation to presentation of Q3 2024 results

TekBot · oktober 24, 2024, 5:01am

Carasent (tidligere Apptix)

Carasent group signs contract to supply Medrave M4 to VGR

Carasent ASA - Minutes from the Annual General Meeting

Carasent ASA - Invitation to presentation of Q1 2024 results

Carasent ASA - announcement of revised financial targets

Carasent ASA - Q1 2024 financial results and presentation

Carasent ASA - Q1 2024 presentation

Contemplated voluntary cash offer to acquire all shares in Carasent ASA

CARASENT COMMENTS ON EG S INTENTION TO LAUNCH VOLUNTARY CASH OFFER

CARASENT COMMENTS FURTHER ON EG S INTENTION TO LAUNCH VOLUNTARY CASH OFFER

Carasent group signs contract to supply Ad Curis to Frelsesarmeen

EG INFORMS CARASENT IT WILL NOT MAKE CONTEMPLATED TAKE-OVER OFFER

Carasent ASA - Invitation to presentation of Q2 2024 results

Carasent ASA - Q2 2024 report and presentation

Carasent ASA - Announcement of cross border merger in connection with relisting to Stockholm

Carasent ASA - Calling notice for extraordinary general meeting

Carasent ASA incentive program for chairman and CEO to be replaced by investments in Carasent SWE shares

Carasent ASA Extraordinary general meeting has approved cross-border merger to effect relisting to Nasdaq Stockholm

Carasent ASA Certain practical information to shareholders in connection with contemplated relisting to Nasdaq Stockholm

Carasent ASA - Invitation to presentation of Q3 2024 results

Carasent ASA - Q3 2024 report and presentation